Abstract: Sequences for detection of SARS-CoV-2, probes and primers that target the target sequences, and methods of use thereof for the detection and diagnosis of SARS-CoV-2 are provided. Detection methods include, but are not limited to, microarray, differential display, RNase protection assay, northern blot, reverse transcriptase (RT) polymerase chain reaction (PCR), and combinations thereof. In preferred embodiments, the detection methods include RT-PCT, more preferably realtime or quantitative RT-PCR, most preferably wherein the RT-PCR includes target specific reverse transcription and/or target specific PCR. In some embodiments, the disclosed primers, probes, compositions, or methods are more sensitive, selective, or combination thereof for SARS-CoV-2 relative to one or more other human- and/or non-human pathogenic coronaviruses and/or respiratory pathogens.

Abstract: Methods for treating, diagnosing, and providing prognostic information for kidney disease related to MERS-CoV infection are described. Transcription and translation products (for example, mRNA or peptides) of FGF2, Smad7, and/or sequences upstream of FGF2 are useful as markers that indicate kidney disease and/or provide prognostic information related to the course of kidney disease related to MERS-CoV infection. Such kidney disease can be treated and/or mitigated by reducing the availability of FGF2, Smad7, and/or a sequence upstream from FGF2 by reducing and/or regulating transcription and by sequestering related peptides using a large molecule binding partner, such as an antibody. Sequences for useful siRNAs and antisense oligonucleotides are provided.

Abstract: Methods for treating, diagnosing, and providing prognostic information for kidney disease related to MERS-CoV infection are described. Transcription and translation products (for example, mRNA or peptides) of FGF2, Smad7, and/or sequences upstream of FGF2 are useful as markers that indicate kidney disease and/or provide prognostic information related to the course of kidney disease related to MERS-CoV infection. Such kidney disease can be treated and/or mitigated by reducing the availability of FGF2, Smad7, and/or a sequence upstream from FGF2 by reducing and/or regulating transcription and by sequestering related peptides using a large molecule binding partner, such as an antibody. Sequences for useful siRNAs and antisense oligonucleotides are provided.